BHUx: A patented polyherbal formulation to prevent hyperlipidemia and atherosclerosis

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 1, 2009, Pages 49-57

  Tripathi, Yamini B ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Anti inflammatory; Atherosclerosis; BHUx; EKO mice; Endothelial dysfunction; Food supplement; Herbal; Hyperlipidemia; M CSF; Vulnerable plaque

Indexed keywords

BHUX FORMULATION; BOSWELLIA SERRATA EXTRACT; CALCIUM ION; COLONY STIMULATING FACTOR 1; COMMIPHORA EXTRACT; FARNESOID X RECEPTOR; HERBACEOUS AGENT; NITRIC OXIDE; PLANT EXTRACT; SEMECARPUS ANACARDIUM EXTRACT; STRYCHNOX NOX VOMICA EXTRACT; TERMENALIA ARJUNA EXTRACT; UNCLASSIFIED DRUG; BHUX POLYHERBAL FORMULATION;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; COMMIPHORA; DRUG MIXTURE; HYPERLIPIDEMIA; MEDICINAL PLANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STRYCHNOX NOX VOMICA; TERMENALIA ARJUNA; TOXICITY TESTING; ANIMAL; AYURVEDA; DISEASE MODEL; DRUG SCREENING; HUMAN; PATENT; PATHOPHYSIOLOGY; PHYTOTHERAPY;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERLIPIDEMIAS; MEDICINE, AYURVEDIC; PATENTS AS TOPIC; PHYTOTHERAPY; PLANT EXTRACTS; TOXICITY TESTS;

EID: 61449113211     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309787158443     Document Type: Review

References (70)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809.
2. Tripathi, Y. B.: US20060147555 ((2006)).
3. Yang G, Lee J, Jung ED, Ham I, Choi HY. Lipid lowering activity of Citri Unshii Pericarpium in hyperlipemic rats. Immunopharmacol Immunotoxicol 2008; 4: 1-9.
4. Brewer HB Jr. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep2007; 9(6): 486-492.
5. Chung DW, Kim WD, Noh SK, Dong MS. Effects of hydrophilic and lipophilic beta-sitosterol derivatives on cholesterol absorption and plasma cholesterol levels in rats. J Agric Food Chem 2008; 56(15): 6665-6670.
6. Berliner, JA, Navab M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms, oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
7. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
9. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbrone MA Jr. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001; 98: 4478-4485.
11. Ge J, Jia Q, Liang C, et al. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 2005; (10): 2157-2163.
12. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J 2008; 84(993): 368-371.
13. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415; (21-23).
14. Rajavashisth TB, Yamada H, Mishra NK. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL: involvement of nuclear factor kB. Arterioscler Thromb Vasc Biol 1995; 15: 1591-1598.
15. Rush JW, Denniss SG, Graham DA. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol 2005; 30(4): 442-474.
16. Pratico D. Antioxidants and endothelium protection. Atherosclerosis 2005; 181(2): 215-224.
17. Wang JM, Griffin JD, Rambaldi A, Chen ZG. Mantovani AI. Induction of monocyte migration by recombinant macrophagecolony stimulating factor. J Immunol 1988; 141: 575-579.
18. Rajavashisth TB, Yamada H, Mishra NK. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL: involvement of nuclear factor kB. Arterioscler Thromb Vasc Biol 1995; 15: 1591-1598.
19. Biwa T, Sakai M, Shichiri M, Horiuchi S. Granulocyte/macrophage colony-stimulating factor plays an essential role in oxidized low density lipoprotein-induced macrophage proliferation. J Atheroscler Thromb 2000; 7(1): 14-20.
20. Fujii K, Masutani M, Okumura T, et al. Frequency and predictor of coronary thin-cap fibroatheroma in patients with acute myocardial infarction and stable angina pectoris a 3-vessel optical coherence tomography study. J Am Coll Cardiol 2008; 52(9): 787-788.
21. Trion A, van der Laarse A. Vascular smooth muscle cells and calcification in ather-sclerosis. Am Heart J 2004; 147: 808-814.
22. Galis ZS, Sukhova GK, Lark MW. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
23. Wada T, McKee MD, Steitz S, Giachelli CM. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res1999; 84: 166 -178.
24. Hirata K, Yokoyama M. Calcium channel blockers and atherosclerosis. Clin Calcium 2004; 14(1): 128-132.
25. Fokko Z, Jorge P. PPARα in atherosclerosis and inflammation. Biochim Biophys Acta 2007; 1771(8): 972-982.
26. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
27. Nakhjavani M, Esteghamati A, Esfahanian F, Ghanei A, Rashidi A, Hashemi S. HbA1c negatively correlates with LCAT activity in type 2 diabetes. Diabetes Res Clin Pract 2008; 81(1): 38-41.
28. Berk BC. Novel approaches to treat oxidative stress and cardiovascular diseases.Trans Am Clin Climatol Assoc 2007; 118: 209-214.
29. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002; 106, 167-169.
30. Sendobry SM, Cornicelli JA, Welch K, et al. Attenuation of dietinduced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br J Pharmacol 1997; 120, 1199-1206.
31. Nieuwenhuizen, W.F., Havekes, A.M., Emeis, J.J.: US20080085939 (2008).
32. Gutzwiller JP, Degen L, Matzinger D, Prestin S, Beglinger C. Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men. Am J Physiol Regul Integr Comp Physiol 2004; 287(3): R562-567.
33. Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters., Am J Physiol Gastrointest Liver Physiol 2008; [Epub ahead of print].
34. Grudell AB, Sweetser S, Camilleri M, et al. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology 2008; 135(4): 1142-54.
35. Mancini MC, Halpern A. Orlistat in the prevention of diabetes in the obese patient. Vasc Health Risk Manag 2008; 4(2): 325-336.
36. Joyce BM, Glaser PE, Gerhardt GA. Adderall produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Psychopharmacology 2007; 191(3): 669-677.
37. Liu, J., Abidi, P., Chen, W., Kraemer, F.B.: US20080124404 (2008).
38. Huang, B., Chen, N., Blair, E.D.: WO2008007063 (2008).
39. Brink, W.D.: WO01005356 (2001).
40. Milburn, M., Milne, J., Auwerx, J., Argmann, C., Lagouge, M., Dipp, M.: WO2007008548 (2007).
41. Heuer, M.A.,Chaudhuri, S.,Clement, K.: WO2008067639 (2008).
42. Uday, S., Sivaram, P., Ish, K.: WO2007143724 (2007).
43. Kim, S. K., Kim, S. W., Lee, S. C., Kim, W.: WO2008038973 (2008).
44. Uday, S., Sivaram, P., Ish, K.: WO2007143724A2 (2007).
45. Bukowski, J. F., Walters, J.: WO2008036807 (2008).
46. Wei, D.: US20036541046 (2003).
47. Morton, N., Seckl, J.R., Walker, B.R., Andrew, R.: EP1420769 (2008).
48. Clement, K., Heuer, Marvin A., Thomas, M., Mason, E.: WO2008049196 ( 2008).
49. Clement, K., Heuer, M.A., Thomas, M., Mason, E.: WO2008049196A1 (2008).
50. Tripathi, Y. B.: WO2004062566A2 (2004).
51. Tripathi YB. Terminalia arjuna extract modulates the concentration of rat aorta induced by KCL and norepinephrine. Phytother Res 1993; 7: 320-322.
52. Agarwal, K. C.: WO2008005275 (2008).
53. Bischof B, Jerger O, Ruzicka LH. Boswellic acids are penta cyclic triterpenic acids belonging to the class of ursane group of triterpenoids. Chim Acta 1949; 32: 1911.
54. Majeed, M., Badmaev, V.: WO00066111A1 (2000).
55. Jauch, J.: WO02085921A3 (2002).
56. Bombardelli, E., Spelta, M.: US5273747 (1993).
57. Bombardelli, E., Spelta, M.: EP0513671 (1992).
58. McCook, John P., Corey, Joseph M., Dorogi, Peter L., Bajor, John S., Knaggs, Helen E., Lange, Beth A., Sharpe, E.: US5690948 (1997).
59. Bombardelli, E., Spelta, M.: US5273747 (1993).
60. Tripathi YB, Tripathi P, Malhotra OP, Tripathi SN. Thyroid stimulatory action of (Z) Guggulsterone: Mechanism of action. Planta Medica 1988; 4: 271-276.
61. Hamied, Y.K.W.: EP0447706 A1 (1991).
62. Yamini B T, Birendra K S, Ravi S P, Mohan K. BHUx: A patent polyherbal formulation to prevent atherosclerosis. eCAM 2005; 2 (2) 217-221.
63. Tripathi YB, Singh BK, Pandey RS, Kumar M. Anti atherogenic role of BHUx: A patent polyherbal formulation. 15th Annual conference of Indian Society for Atherosclerosis Research, Tirupati, India 2002.
64. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296, 1703-1706.
65. Tripathi Y B. Personal Communication 2008.
66. Cornicelli JA, Trivedi BK. 15-Lipoxygenase and its inhibition: A novel therapeutic target for vascular diseases. Curr Pharm Design 1999; 5, 11-20.
67. Tripathi YB, Reddy MM, Pandey RS, et al. Anti-inflammatory properties of BHUx, a polyherbal formulation to prevent atherosclerosis. Inflammopharmacology 2004; 12(2): 131-152.
68. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colonystimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150(5): 1687-1699.
69. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm 2008; 14(4): 338-351.
70. Griess JP. Bemerkungen zu der Abhandlung der HH: Wesely und Benedikt "Über einige Azoverbindungen". Ber Deutsch Chem Ges 1879; 12: 426-428.